#USA #Belgrade #Xtant Medical #BioHorizons #Prolifica

Xtant Medical and BioHorizons: A Strategic Partnership

Xtant Medical Holdings, Inc. has recently entered into a significant collaboration with BioHorizons, a subsidiary of Henry Schein, Inc., aimed at enhancing the availability of Xtant's allogeneic growth factor technology in the dental market. Announced on August 27, 2026, this exclusive partnership designates BioHorizons as the sole distributor of Xtant's innovative allogeneic growth factor, branded as Prolifica™, throughout the United States and Canada.

This partnership is poised to revolutionize the accessibility of advanced allograft technologies for dental professionals, reflecting the synergistic strengths of both companies. Xtant, which specializes in surgical solutions for conditions requiring regenerative medicine, merges its expertise in biologics with BioHorizons' entrenched commercial reach and established relationships within the dental community.

The Significance of the Partnership

Sean Browne, the President and CEO of Xtant Medical, highlighted the importance of this exclusive relationship, stating, "This collaboration unifies our proficiency in regenerative biologics with BioHorizons' trusted market presence. We are excited about the potential benefits this partnership brings to both clinicians and their patients."

Similarly, Steve Boggan, President and CEO of BioHorizons, remarked on the strategic fit of Prolifica™ within their portfolio, emphasizing that this partnership allows for the distribution of allogeneic growth factors to a wider range of clinicians who depend on their services.

Prolifica™ is a sophisticated allograft that comprises a naturally occurring blend of growth factors, secured by native human collagen. This formulation is processed to maintain the natural, biphasic release of proteins, an aspect crucial for supporting bone healing and regeneration in various clinical applications.

Expected Outcomes and Industry Impact

Both Xtant and BioHorizons anticipate that this collaboration will create a long-lasting distribution channel that not only expands the reach of Prolifica™ but also lays the groundwork for further cooperation between the two organizations in future endeavors. With a focus on improving patient outcomes, this partnership aims to leverage the strengths and capabilities of both companies in the regenerative medicine field.

The introduction of Prolifica™ through BioHorizons' extensive commercial network signifies a commitment to enhancing patient care standards in dentistry and oral-maxillofacial procedures. As clinicians get access to this innovative technology, the potential for improved recovery times and outcomes in bone healing processes significantly rises.

Looking Ahead

As Xtant Medical continues to pursue its mission of honoring the gift of donor tissue to enhance patients’ quality of life, this partnership serves as a crucial step toward achieving that goal. Right from the conceptualization and design of the allograft to its market entry, the joint efforts of Xtant and BioHorizons promise to usher in a new era for dental regenerative treatments.

In conclusion, Xtant Medical’s strategic partnership with BioHorizons not only broadens the availability of advanced allogeneic growth factors to a wider audience but also serves the broader objective of improving healthcare outcomes through innovative solutions in regenerative medicine. With Prolifica™ now integrated into their offerings, BioHorizons strengthens its position in the marketplace, benefiting clinicians and patients alike.